MD Anderson Division of Cancer Medicine
Welcome,         Profile    Billing    Logout  
 17 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Garcia-Manero, Guillermo
NCI-2018-01238, NCT03094637: Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

Active, not recruiting
2
40
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome
11/21
11/23
NCI-2014-02377, NCT02131597: Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes

Active, not recruiting
2
71
US
Guadecitabine, DNMT inhibitor SGI-110, S110, SGI-110
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
High Risk Myelodysplastic Syndrome
11/24
11/24
STIMULUS MDS-US, NCT04878432: : Sabatolimab Added to HMA in Higher Risk MDS

Active, not recruiting
2
39
US
MBG453, sabatolimab, Azacitidine, Decitabine, INQOVI (oral decitabine)
Novartis Pharmaceuticals
Myelodysplastic Syndrome (MDS)
09/23
06/24
NCT02530463: Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

Active, not recruiting
2
99
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome
09/25
09/25
NCT02269280: Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Active, not recruiting
2
268
US
Azacitidine (AZA) Days 1 - 3, 5-Azacytidine, 5-AZA, Vidaza, 5-AZC, AZA-CR, Ladakamycin, NSC-102816, Azacytidine, Decitabine (DAC), Dacogen, Best Supportive Care (BSC), Azacitidine (AZA) Days 1 - 5
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Leukemia
10/26
10/27
NCI-2019-08494, NCT04239157: A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Recruiting
2
60
US
Canakinumab, ACZ885, Ilaris
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Novartis
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
12/26
12/26
KCP-8602-801, NCT02649790: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Checkmark From trial for myelodysplastic syndrome at ASH 2019
Dec 2019 - Dec 2019: From trial for myelodysplastic syndrome at ASH 2019
Active, not recruiting
1/2
277
Europe, Canada, US, RoW
KPT-8602, Eltanexor, ASTX727, Dexamethasone
Karyopharm Therapeutics Inc
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
08/24
12/24
NCT04160052: Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Checkmark Data from P1 trial for high-risk MDS and CML
Oct 2022 - Oct 2022: Data from P1 trial for high-risk MDS and CML
Recruiting
1/2
116
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, Onureg, U-18496, Vidaza, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
12/25
12/25
NCT05682170: Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

Jul 2023 - Dec 2023: Preliminary data from trial in combination with ZN-d5 for r/r/ AML
Recruiting
1/2
95
US
ZN-d5 ZN-c3, Study Drug, ZN-c3
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Acute Myeloid Leukemia (AML)
03/25
02/26
NCT04550442: Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recruiting
1/2
58
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Genentech, Inc.
Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
05/25
05/25
CA-4948-102, NCT04278768: Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS

Recruiting
1/2
366
Europe, US, RoW
Emavusertib, CA-4948, Venetoclax
Curis, Inc.
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
04/26
04/26
CTX-712-CL-02, NCT05732103: A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Recruiting
1/2
170
US
CTX-712
Chordia Therapeutics, Inc., Theradex
Acute Myeloid Leukemia, Myelodysplastic Syndromes
04/26
04/28
NCT04655755: Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recruiting
1/2
52
US
Decitabine and Cedazuridine, ASTX727, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, Inqovi, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, Astex Pharmaceuticals, Inc., Genentech, Inc.
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
07/26
07/26
NCT04810611: Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Terminated
1
33
Europe, US, RoW
MBG453, sabatolimab, NIS793, canakinumab, ACZ885
Novartis Pharmaceuticals
Myelodysplastic Syndromes
04/24
04/24
NCT04227847: A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Recruiting
1
140
Europe, US
SEA-CD70, azacitidine, VIDAZA
Seagen Inc.
Myelodysplastic Syndrome, Acute Myeloid Leukemia
12/24
11/26
NCT06113302: A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Recruiting
1
40
US
Luspatercept, ACE-536
M.D. Anderson Cancer Center
Myelodysplastic Syndromes
06/26
06/26

Download Options